Advertisement

Clinical Drug Investigation

, Volume 36, Issue 7, pp 519–530 | Cite as

Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995

  • Yoko Murphy
  • Emily Wilson
  • Elliot M. Goldner
  • Benedikt Fischer
Review Article

Abstract

Benzodiazepines are commonly prescribed psycho-pharmaceuticals (e.g., for anxiety, tension, and insomnia); they are generally considered safe but have potential adverse effects. Benzodiazepine use in Canada versus internationally is comparably high, yet no recent comprehensive review of use, misuse, or related (e.g., morbidity, mortality) harm at the population level exists; the present review aimed to fill this gap. We searched four key scientific literature databases (Medline, CINAHL, EBM Reviews, and Web of Science) with relevant search terms, and collected relevant “gray literature” (e.g., survey, monitoring, government reports) data published in 1995–2015. Two reviewers conducted data screening and extraction; results were categorized and narratively summarized by key sub-topics. Levels of benzodiazepine use in the general population have been relatively stable in recent years; medical use is generally highest among older adults. Rates of non-medical use are fairly low in general but higher in marginalized (e.g., street drug use) populations; high and/or inappropriate prescribing appears common in older adults. Benzodiazepines are associated with various morbidity outcomes (e.g., accidents/injuries, cognitive decline, sleep disturbances, or psychiatric issues), again commonly observed in older adults; moreover, benzodiazepines are identified as a contributing factor in suicides and poisoning deaths. Overall there is a substantial benzodiazepine-related health problem burden—although lower than that for other psycho-medications (e.g., opioids)—in Canada, mainly as a result of overuse and/or morbidity. National benzodiazepine prescription guidelines are lacking, and few evaluated interventions to reduce benzodiazepine-related problems exist. There is a clear need for reducing inappropriate benzodiazepine use and related harm in Canada through improved evidence-based practice as well as monitoring and control.

Keywords

Chronic Obstructive Pulmonary Disease British Columbia Zopiclone Methadone Maintenance Treatment Prescription Opioid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with Ethical Standards

Funding

Dr. Fischer acknowledges funding support from a Canadian Institutes of Health Research [CIHR/Public Health Agency of Canada (PHAC)] Applied Public Health Research Chair Award, and the CIHR CRISM Node Team Grant (SMN-139150). The other authors have no funding to declare.

Conflict of interest

Yoko Murphy, Emily Wilson, Elliot M. Goldner, and Benedikt Fischer have no conflicts of interest to declare.

References

  1. 1.
    Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: Pharmacokinetics, dependency, rebound and withdrawal. Canadian society for clinical pharmacology. Can J Clin Pharmacol. 1999;6(2):69–83.PubMedGoogle Scholar
  2. 2.
    Tallman JF, Paul SM, Skolnick P, Gallager DW. Receptors for the age of anxiety: pharmacology of the benzodiazepines. Science. 1980;207(4428):274–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Sternbach LH. The benzodiazepine story. Prog Drug Res. 1978;22:229–66.PubMedGoogle Scholar
  4. 4.
    Rose N. Neurochemical selves. Society. 2003;41(1):46–59.CrossRefGoogle Scholar
  5. 5.
    Pieters T, Snelders S. Psychotropic drug use: between healing and enhancing the mind. Neuroethics. 2009;2(2):63–73.CrossRefGoogle Scholar
  6. 6.
    Brands B. Drugs and drug abuse: a reference text. Toronto: Addiction Research Foundation; 1998.Google Scholar
  7. 7.
    Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994;48(1):25–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Longo LP, Johnson B. Addiction: Part I. benzodiazepines–side effects, abuse risk and alternatives. Am Fam Physician. 2000;61(7):2121–8.PubMedGoogle Scholar
  9. 9.
    Ciraulo DA, Sarid-Segal O. Benzodiazepines: Abuse liability. In: Roy-Byrne PP, Cowley DS, editors. Benzodiazepines in clinical practice: risks and benefits. Washington, DC: American Psychiatric Press, Inc.; 1991. p. 155–74.Google Scholar
  10. 10.
    World Health Organization (WHO). Programme on substance abuse. Rational use of benzodiazepines. Copenhagen: World Health Organization; 1996.Google Scholar
  11. 11.
    International Narcotics Control Board (INCB). Narcotic drugs estimated world requirements for 2014—statistics for 2012. New York: United Nations; 2014. Report No.: T.14.XI.2.Google Scholar
  12. 12.
    Busto U. Benzodiazepine use and abuse in Canada. CMAJ. 1989;141(9):917–21.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Cooperstock R, Hill J. The effects of tranquillization: benzodiazepine use in Canada. Ottawa: Health and Welfare Canada; 1982.Google Scholar
  14. 14.
    Morgan SG, Barer ML, Agnew JD. Whither seniors’ pharmacare: Lessons from (and for) Canada. Health Aff (Millwood). 2003;22(3):49–59.PubMedCrossRefGoogle Scholar
  15. 15.
    Anis AH, Guh D, Wang X. A dog’s breakfast: Prescription drug coverage varies widely across Canada. Med Care. 2001;39(4):315–26.PubMedCrossRefGoogle Scholar
  16. 16.
    International Narcotics Control Board (INCB). Report of the International Narcotics Control Board for 2004. New York: United Nations; 2005. Report No.: E.05.XI.3.Google Scholar
  17. 17.
    Morgan S, Smolina K, Mooney D, Raymond C, Bowen M, Gorczynski C, et al. The Canadian Rx Atlas. 3rd ed. Vancouver: UBC Centre for Health Services and Policy Research; 2013.Google Scholar
  18. 18.
    Canadian alcohol and drug use monitoring survey (CADUMS): summary of results for 2012 [Internet]; 2014. Available from: http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.php.
  19. 19.
    Veldhuizen S, Wade TJ, Cairney J. Alcohol consumption among Canadians taking benzodiazepines and related drugs. Pharmacoepidemiol Drug Saf. 2009;18(3):203–10.PubMedCrossRefGoogle Scholar
  20. 20.
    Patten SB, Williams JVA, Lavorato DH, Kassam A, Sabapathy CD. Pharmacoepidemiology of benzodiazepine and sedative-hypnotic use in a Canadian general population cohort during 12 years of follow-up. Can J Psychiatry. 2010;55(12):792–9.PubMedGoogle Scholar
  21. 21.
    Neutel CI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry. 2005;17(3):189–97.PubMedCrossRefGoogle Scholar
  22. 22.
    Vozoris NT, Leung RS. Sedative medication use: prevalence, risk factors, and associations with body mass index using population-level data. Sleep. 2011;34(7):869–74.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Sanyal C, Asbridge M, Kisely S, Sketris I, Andreou P. The utilization of antidepressants and benzodiazepines among people with major depression in Canada. Can J Psychiatry. 2011;56(11):667–76.PubMedGoogle Scholar
  24. 24.
    Beck CA, Williams JV, Wang JL, Kassam A, El-Guebaly N, Currie SR, et al. Psychotropic medication use in canada. Can J Psychiatry. 2005;50(10):605–13.PubMedGoogle Scholar
  25. 25.
    Hogan DB, Maxwell CJ, Fung TS, Ebly EM. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian study of health and aging. Can J Clin Pharmacol. 2003;10(2):72–7.PubMedGoogle Scholar
  26. 26.
    Ebly EM, Hogan DB, Fung TS. Potential adverse outcomes of psychotropic and narcotic drug use in Canadian seniors. J Clin Epidemiol. 1997;50(7):857–63.PubMedCrossRefGoogle Scholar
  27. 27.
    Cunningham CM, Hanley GE, Morgan S. Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy. 2010;97(2):122–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001–2006). Clin Ther. 2012;34(1):239–49.PubMedCrossRefGoogle Scholar
  29. 29.
    Hagen BF, Armstrong-Esther C, Quail P, Williams RJ, Norton P, Navenec CL, et al. Neuroleptic and benzodiazepine use in long-term care in urban and rural alberta: characteristics and results of an education intervention to ensure appropriate use. Int Psychogeriatr. 2005;17(4):631–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Esposito E, Barbui C, Patten SB. Patterns of benzodiazepine use in a Canadian population sample. Epidemiol Psichiatr Soc. 2009;18(3):248–54.PubMedGoogle Scholar
  31. 31.
    Alessi-Severini S, Bolton JM, Enns MW, Dahl M, Collins DM, Chateau D, et al. Use of benzodiazepines and related drugs in manitoba: a population-based study. CMAJ Open. 2014;2(4):E208–16.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Neutel CI, Maxwell CJ. The benzodiazepine treadmill–does one prescription lead to more? Pharmacoepidemiol Drug Saf. 1996;5(1):39–42.PubMedCrossRefGoogle Scholar
  33. 33.
    Ohayon MM, Caulet M. Insomnia and psychotropic drug consumption. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(3):421–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Tu K, Mamdani MM, Hux JE, Tu J. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc. 2001;49:1341–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Hogan DB, Maxwell CJ, Fung TS, Ebly EM. Regional variation in the use of medications by older Canadians—a persistent and incompletely understood phenomena. Pharmacoepidemiol Drug Saf. 2003;12(7):575–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Préville M, Bossé C, Vasiliadis H, Voyer P, Laurier C, Berbiche D, et al. Correlates of potentially inappropriate prescriptions of benzodiazepines among older adults: results from the ESA study. Can J Aging La Revue canadienne du vieillissement. 2012;31(3):313–22.CrossRefGoogle Scholar
  37. 37.
    Conn DK, Ferguson I, Mandelman K, Ward C. Psychotropic drug utilization in long-term-care facilities for the elderly in Ontario,Canada. Int Psychogeriatr. 1999;11(3):223–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Vozoris NT, Fischer HD, Wang X, Stephenson AL, Gershon AS, Gruneir A, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014;44(2):332–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Vozoris NT, Fischer HD, Wang X, Anderson GM, Bell CM, Gershon AS, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30(3):183–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Bartlett G, Abrahamowicz M, Grad R, Sylvestre MP, Tamblyn R. Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons. BMC Fam Pract. 2009;10(1):1–8.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Fortin D, Preville M, Ducharme C, Hebert R, Trottier L, Gregoire JP, et al. Factors associated with long-term benzodiazepine use among elderly women and men in quebec. J Women Aging. 2007;19(3–4):37–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Tamblyn R, Abrahamowicz M, du Berger R, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc. 2005;53(2):233–41.PubMedCrossRefGoogle Scholar
  43. 43.
    Egan M, Moride Y, Wolfson C, Monette J. Long-term continuous use of benzodiazepines in older adults in Quebec: prevalence, incidence and risk factors. J Am Geriatr Soc. 2000;48(7):811–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of benzodiazepine and related drug use in Nova Scotia and Australia. Can J Psychiatry. 2008;53(8):545–52.PubMedGoogle Scholar
  45. 45.
    Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf. 2008;17(7):697–706.PubMedCrossRefGoogle Scholar
  46. 46.
    Rojas-Fernandez CH, Carver D, Tonks R. Population trends in the prevalence of benzodiazepine use in the older population of Nova Scotia: a cause for concern? Can J Clin Pharmacol. 1999;6(3):149–56.PubMedGoogle Scholar
  47. 47.
    Laurier C, Moride Y, Kennedy WA. Health survey data on potentially inappropriate geriatric drug use. Ann Pharmacother. 2002;36(3):404–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Voyer P, Preville M, Cohen D, Berbiche D, Beland SG. The prevalence of benzodiazepine dependence among community-dwelling older adult users in Quebec according to typical and atypical criteria. Can J Aging. 2010;29(2):205–13.PubMedCrossRefGoogle Scholar
  49. 49.
    Voyer P, Cappeliez P, Pérodeau G, Préville M. Mental health for older adults and benzodiazpine use. J Community Health Nurs. 2005;22(4):213–29.PubMedCrossRefGoogle Scholar
  50. 50.
    Summary of results of the 2010-11 youth smoking survey [Internet]; 2012. Available from: http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_survey-sondage_2010-2011/result-eng.php.
  51. 51.
    Summary of results of the 2012-13 youth smoking survey [Internet]; 2014. Available from: http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_survey-sondage_2012-2013/result-eng.php.
  52. 52.
    Boak A, Hamilton HA, Adlaf EM, Mann RE. Drug use among Ontario students, 1977–2013: Detailed OSDUHS findings. Toronto: Centre for Addiction and Mental Health; 2013. Report No.: CAMH Research Document Series No. 36.Google Scholar
  53. 53.
    Gupta N, Wang H, Collette M, Pilgrim W. New Brunswick student drug use survey report 2012. Fredericton: Department of Health; 2013.Google Scholar
  54. 54.
    Asbridge M, Langille D. Nova Scotia student drug use survey 2012: technical report. Halifax: Dalhousie University; 2013.Google Scholar
  55. 55.
    Poulin C, Elliot D. Student drug use survey in the Atlantic provinces 2007: atlantic technical report. Halifax: Dalhousie University, Community Health and Epidemiology; 2007. Report No.: C2007-906454-X.Google Scholar
  56. 56.
    Department of Health and Community Services. Newfoundland and Labrador 2012 student drug use survey: Highlights report. St. John’s, Newfoundland and Labrador: Government of Newfoundland and Labrador; 2013.Google Scholar
  57. 57.
    Cheverie C, Henry S, MacSwain M, McClure C, Sanford C. Prince Edward Island student drug use 2004–2011. Charlottetown: Prince Edward Island Department of Health and Wellness; 2013.Google Scholar
  58. 58.
    Adlaf EM, Demers A, Gliksman L. Canadian campus survey 2004. Toronto: Centre for Addiction and Mental Health; 2005.Google Scholar
  59. 59.
    Barrett S, Darredeau C, Pihl R. Patterns of simultaneous polysubstance use in drug using university students. Hum Psycholpharmacol. 2006;21(4):255–63.CrossRefGoogle Scholar
  60. 60.
    The First Nations Information Governance Centre. First Nations regional health survey (RHS) phase 2 (2008/10) national report on adults, youth and children living in First Nations communities. Ottawa: The First Nations Information Governance Centre; 2012.Google Scholar
  61. 61.
    Public Health Agency of Canada. I-track: Enhanced surveillance of risk behaviours among people who inject drugs—phase I report. Ottawa: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; 2006.Google Scholar
  62. 62.
    Public Health Agency of Canada. I-track: Enhanced surveillance of HIV, hepatitis C and associated risk behaviours among people who inject drugs in Canada. Phase 2 report. Ottawa: Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada; 2014.Google Scholar
  63. 63.
    Fischer B, Cruz MF, Rehm J. Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN). Can J Psychiatry. 2006;51(10):624–34.PubMedGoogle Scholar
  64. 64.
    Patra J, Fischer B, Maksimowska S, Rehm J. Profiling poly-substance use typologies in a multi-site cohort of illicit opioid and other drug users in Canada—a latent class analysis (LCA). Addict Res Theory. 2009;17(2):168–85.CrossRefGoogle Scholar
  65. 65.
    Fischer B, Patra J, Cruz MF, Gittins J, Rehm J. Comparing prescription opioid and heroin users in a canadian multi-site cohort of illicit opioid and other drug users. Drug Alcohol Rev. 2008;27(6):625–32.PubMedCrossRefGoogle Scholar
  66. 66.
    Wild C, Wolfe J, Newton-Taylor M, Kang H. Prescription drug misuse in Edmonton and Alberta: a rapid assessment. Edmonton: Addiction and Mental Health Research Laboratory; 2008.Google Scholar
  67. 67.
    Erickson A, Becker M, Shaw S, Kasper K, Keynan Y. Substance use and its impact on care outcomes among HIV-infected individuals in Manitoba. AIDS Care. 2015;27(9):1168–73.PubMedCrossRefGoogle Scholar
  68. 68.
    Brands B, Blake J, Marsh D, Sproule B, Jeyapalan R, Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis. 2008;27(3):37–48.PubMedCrossRefGoogle Scholar
  69. 69.
    Fulton HG, Barrett SP, Macisaac C, Stewart SH. The relationship between self-reported substance use and psychiatric symptoms in low-threshold methadone maintenance treatment clients. Harm Reduct J. 2011;8(18):1–10.Google Scholar
  70. 70.
    Fraser A, Zamecnik J. Substance abuse monitoring by the correctional service of Canada. Ther Drug Monit. 2002;24:187–91.PubMedCrossRefGoogle Scholar
  71. 71.
    Fraser A, Zamecnik J, Keravel J, McGrath L, Wells J. Experience with urine drug testing by the correctional service of Canada. Forensic Sci Int. 2001;121:16–22.PubMedCrossRefGoogle Scholar
  72. 72.
    Fraser AD. Urine drug testing for social service agencies in Nova Scotia, Canada. J Forensic Sci. 1998;43(1):194–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Fraser AD. A 6-year experience with urine drug testing by family service agencies in Nova Scotia,Canada. Forensic Sci Int. 2001;121(3):151–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Canadian Institute for Health Information. National trauma registry bulletin (1999–2000). Ottawa: Canadian Institute for Health Information; 2002.Google Scholar
  75. 75.
    Drug and Alcohol Treatment Information System (DATIS). Substance abuse statistical tables: Fiscal year 2007/2008 to fiscal year 2012/2013. Toronto: Centre for Addiction and Mental Health; 2013.Google Scholar
  76. 76.
    Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res. 2004;67(2–3):157–66.PubMedCrossRefGoogle Scholar
  77. 77.
    Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defect Res B. 2008;83(1):68–76.CrossRefGoogle Scholar
  78. 78.
    Dussault C, Lemire A, Bouchard J, Brault M. Drug use among Quebec drivers: the 1999 roadside survey. In: Proceedings of the 15th international conference on alcohol, drugs and traffic safety; 2000.Google Scholar
  79. 79.
    Neutel CI. Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol Clin Exp. 1998;13(S2):S115–23.CrossRefGoogle Scholar
  80. 80.
    Maxwell CJ, Neutel CI, Hirdes JP. A prospective study of falls after benzodiazepine use: a comparison of new and repeat use. Pharmacoepidemiol Drug Saf. 1997;6(1):27–35.PubMedCrossRefGoogle Scholar
  81. 81.
    Woodall KL, Chow BLC, Lauwers A, Cass D. Toxicological findings in fatal motor vehicle collisions in Ontario, Canada: a one-year study. J Forensic Sci. 2015;60(3):669–74.PubMedCrossRefGoogle Scholar
  82. 82.
    Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25(4):273–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Préville M, Boyer R, Grenier S, Dubé M, Voyer P, Punti R, et al. The epidemiology of psychiatric disorders in Quebec’s older adult population. Can J Psychiatry. 2008;53(12):822–32.PubMedGoogle Scholar
  84. 84.
    Beland SG, Preville M, Dubois MF, Lorrain D, Grenier S, Voyer P, et al. Benzodiazepine use and quality of sleep in the community-dwelling elderly population. Aging Ment Health. 2010;14(7):843–50.PubMedCrossRefGoogle Scholar
  85. 85.
    Beland SG, Preville M, Dubois MF, Lorrain D, Voyer P, Bosse C, et al. The association between length of benzodiazepine use and sleep quality in older population. Int J Geriatr Psychiatry. 2011;26(9):908–15.PubMedCrossRefGoogle Scholar
  86. 86.
    Voyer P, McCubbin M, Preville M, Boyer R. Factors in duration of anxiolytic, sedative, and hypnotic drug use in the elderly. Can J Nurs Res. 2003;35(4):126–49.PubMedGoogle Scholar
  87. 87.
    Lagnaoui R, Tournier M, Moride Y, Wolfson C, Ducruet T, Bégaud B, et al. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing. 2009;38(2):226–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;9(349):g5205.CrossRefGoogle Scholar
  89. 89.
    Voaklander DC, Kelly KD, Rowe BH, Schopflocher DP, Svenson L, Yiannakoulias N, et al. Pain, medication, and injury in older farmers. Am J Ind Med. 2006;49(5):374–82.PubMedCrossRefGoogle Scholar
  90. 90.
    Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278(1):27–31.PubMedCrossRefGoogle Scholar
  91. 91.
    Dhalla IA, Anderson GM, Mamdani MM, Bronskill SE, Sykora K, Rochon PA. Inappropriate prescribing before and after nursing home admission. J Am Geriatr Soc. 2002;50(6):995–1000.PubMedCrossRefGoogle Scholar
  92. 92.
    Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007;87(1):39–45.PubMedCrossRefGoogle Scholar
  93. 93.
    Ickowicz S, Hayashi K, Dong H, Milloy MJ, Kerr T, Montaner JS, et al. Benzodiazepine use as an independent risk factor for HIV infection in a canadian setting. Drug Alcohol Depend. 2015;1(155):190–4.CrossRefGoogle Scholar
  94. 94.
    Fischer B, Brissette S, Brochu S, Bruneau J, el-Guebaly N, Noel L, et al. Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. CMAJ. 2004;171(3):235–9.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Busto U, Romach M, Sellers E. Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence. J Clin Psychopharmacol. 1996;16(1):51–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Rizvi SJ, Sproule BA, Gallaugher L, McIntyre RS. Correlates of benzodiazepine use in major depressive disorder: the effect of anhedonia. J Affect Disord. 2015;187:101–5.PubMedCrossRefGoogle Scholar
  97. 97.
    Belleville G. Mortality hazard associated with anxiolytic and hypnotic drug use in the national population health survey. Can J Psychiatry. 2010;55(9):558–67.PubMedGoogle Scholar
  98. 98.
    Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183(7):E411–9.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181(12):891–6.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Leece P, Cavacuiti C, Macdonald EM, Gomes T, Kahan M, Srivastava A, et al. Predictors of opioid-related death during methadone therapy. J Subst Abuse Treat. 2015;15(57):30–5.CrossRefGoogle Scholar
  101. 101.
    Neutel CI, Patten SB. Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol. 1997;7(8):568–74.PubMedCrossRefGoogle Scholar
  102. 102.
    Voaklander DC, Rowe BH, Dryden DM, Pahal J, Saar P, Kelly KD. Medical illness, medication use and suicide in seniors: a population-based case–control study. J Epidemiol Community Health. 2008;62(2):138–46.PubMedCrossRefGoogle Scholar
  103. 103.
    Poulin C, Stein J, Butt J. Surveillance of drug overdose deaths using medical examiner data. Chronic Dis Can. 1998;19(4):177–82.PubMedGoogle Scholar
  104. 104.
    Kassam A, Carter B, Patten SB. Sedative hypnotic use in Alberta. Can J Psychiatry. 2006;51(5):287–94.PubMedGoogle Scholar
  105. 105.
    Ontario Ministry of Health. Ontario health survey 1990. Toronto: Ministry of Health; 1994. Report No.: 2nd edition.Google Scholar
  106. 106.
    Canadian community health survey - mental health [Internet]; 2012. Available from: http://www5.statcan.gc.ca/cansim/a26?id=1051101&retrLang=eng&lang=eng.
  107. 107.
    Davidson JR. Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. J Clin Psychiatry. 2004;65(Suppl 5):29–33.PubMedGoogle Scholar
  108. 108.
    Morin CM, LeBlanc M, Belanger L, Ivers H, Merette C, Savard J. Prevalence of insomnia and its treatment in canada. Can J Psychiatry. 2011;56(9):540–8.PubMedGoogle Scholar
  109. 109.
    Crowley K. Sleep and sleep disorders in older adults. Neuropsychol Rev. 2011;21(1):41–53.PubMedCrossRefGoogle Scholar
  110. 110.
    Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169–73.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Mah L, Upshur RE. Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician perceptions. BMC Fam Pract. 2002;8(3):9.CrossRefGoogle Scholar
  112. 112.
    Fischer B, Keates A, Buhringer G, Reimer J, Rehm J. Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in north America compared to the rest of the world? Addiction. 2014;109(2):177–81.PubMedCrossRefGoogle Scholar
  113. 113.
    Morin CM, Vallieres A, Guay B, Ivers H, Savard J, Merette C, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301(19):2005–15.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Morgenthaler T, Kramer M, Alessi C, Friedman L, Boehlecke B, Brown T, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American academy of sleep medicine report. Sleep. 2006;29(11):1415–9.PubMedGoogle Scholar
  115. 115.
    Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician. 2012;15(3 Suppl):ES191–203.PubMedGoogle Scholar
  116. 116.
    Fischer B, Gooch J, Goldman B, Kurdyak P, Rehm J. Non-medical prescription opioid use, prescription opioid-related harms and public health in canada: an update 5 years later. Can J Public Health. 2014;105(2):146–9.Google Scholar
  117. 117.
    Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–9.PubMedCrossRefGoogle Scholar
  118. 118.
    McMillan JM, Aitken E, Holroyd-Leduc JM. Management of insomnia and long-term use of sedative-hypnotic drugs in older patients. CMAJ. 2013;185(17):1499–505.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    National Association of Pharmacy Regulatory Authorities. Benzodiazepine regulations. Ottawa: NAPRA; 2001.Google Scholar
  120. 120.
    Currie J. Manufacturing addiction: the overprescription of benzodiazepines and sleeping pills to women in Canada. Vancouver: British Columbia Centre of Excellence for Women’s Health; 2003.Google Scholar
  121. 121.
    Furlan AD, Reardon R, Weppler C, NOUGG, For the National Opioid Use Guideline Group (NOUGG), National Opioid Use Guideline Group. Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ. 2010;182(9):923–30.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(Suppl 1):S26–43.PubMedCrossRefGoogle Scholar
  123. 123.
    Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006;51(8 Suppl 2):9S–91S.Google Scholar
  124. 124.
    Anthierens S, Pasteels I, Habraken H, Steinberg P, Declercq T, Christiaens T. Barriers to nonpharmacologic treatments for stress, anxiety, and insomnia: Family physicians’ attitudes toward benzodiazepine prescribing. Can Fam Physician. 2010;56(11):e398–406.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry. 2003;160(8):1432–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Rogers A, Pilgrim D, Brennan S, Sulaiman I, Watson G, Chew-Graham C. Prescribing benzodiazepines in general practice: a new view of an old problem. Health (London). 2007;11(2):181–98.PubMedCrossRefGoogle Scholar
  127. 127.
    Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77–84.PubMedCrossRefGoogle Scholar
  128. 128.
    Locke AB, Kirst N, Shultz CG. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;91(9):617–24.PubMedGoogle Scholar
  129. 129.
    Eagles L. Guidance for prescribing and withdrawal of benzodiazepines and hypnotics in general practice. Aberdeen: NHS Grampian; 2008. Report No.: 1.Google Scholar
  130. 130.
    el-Guebaly N, Sareen J, Stein MB. Are there guidelines for the responsible prescription of benzodiazepines? Can J Psychiatry. 2010;55(11):709–14.PubMedGoogle Scholar
  131. 131.
    Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN. Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. CMAJ. 2012;184(16):E852–6.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Gomes T, Juurlink D, Yao Z, Camacho X, Paterson JM, Singh S, et al. Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in ontario: A time series analysis. CMAJ Open. 2014;2(4):256–61.CrossRefGoogle Scholar
  133. 133.
    Pimlott NJ, Hux JE, Wilson LM, Kahan M, Li C, Rosser WW. Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. CMAJ. 2003;168(7):835–9.PubMedPubMedCentralGoogle Scholar
  134. 134.
    Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Yoko Murphy
    • 1
  • Emily Wilson
    • 2
  • Elliot M. Goldner
    • 2
  • Benedikt Fischer
    • 1
    • 3
    • 4
  1. 1.Social and Epidemiological Research, Centre for Addiction and Mental Health (CAMH)TorontoCanada
  2. 2.Faculty of Health SciencesCentre for Applied Research in Mental Health and Addictions (CARMHA), Simon Fraser UniversityVancouverCanada
  3. 3.Department of PsychiatryUniversity of TorontoTorontoCanada
  4. 4.Institute of Medical ScienceUniversity of TorontoTorontoCanada

Personalised recommendations